Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC

Prior treatment

• Active or previously documented autoimmune or inflammatory diseases (including inflammatory bowel disease, diverticulitis \[except diverticular disease\], systemic lupus erythematosus, Sarcoidosis syndrome, Wegener' s syndrome).
• Patients with uncontrolled concurrent diseases, including but not limited to persistent or active infection (including tuberculosis, hepatitis B, hepatitis C, human immunodeficiency virus, etc.), symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled arrhythmia, active interstitial lung disease, severe chronic gastrointestinal disease with diarrhea or mental illness.
• Ongoing or prior use of immunosuppressive agents within 14 days prior to first dose

Other illness

• Patients with other active malignancies within 5 years or at the same time.
• History of allogeneic organ transplantation.
• History of active primary immunodeficiency.
• Allergic to research drug ingredients.

Lab values

• Pathologic type was adenocarcinoma with EGFR gene mutation or ALK gene rearrangement.

Other

• Women of child-bearing potential who are pregnant or breastfeeding.
• The investigator judged other situations not suitable for inclusion in this study.

• Age 18-75 years; ECOG score 0-1.
• Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).
• Unresectable Stage II-III NSCLC (according to AJCC 8th edition) with maximum tumor diameter T ≥ 5 cm in the primary tumor or minimum diameter N ≥ 2 cm in mediastinal metastatic lymph nodes.
• No other previous anti-tumor history, at least 3 months of expected survival.
• No serious medical diseases and dysfunction of major organs, such as blood routine, liver, kidney, heart and lung function.